Skip to Content

Merck & Co Inc

MRK: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$144.00DzvlqTrkzdwgs

Merck Earnings: Strong Results Led by Keytruda and Gardasil as Pipeline Makes Strides

Merck reported strong second-quarter results slightly above our expectations and raised full-year 2023 guidance, but we don’t expect any major changes to Merck’s fair value estimate based on the minor outperformance.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center